Compare Stocks: APRE, EDSA, CNTX, and RNAZ

Comparative Price Performance Over Time

Compare Price & Volume

Company	Current Price	50-Day Moving Average	52-Week Range	Market Cap	Beta	Avg. Volume	Today's Volume
APRE Aprea Therapeutics	$0.58 -2.8%	$0.73	$0.55 ▼ $1.69	$7.34M	1.66	879,083 shs	74,287 shs
CNTX Context Therapeutics	$0.26 -7.1%	$0.40	$0.25 ▼ $3.62	$23.49M	1.71	1.75 million shs	954,340 shs
EDSA Edesa Biotech	$2.65 -7.0%	$4.46	$0.72 ▼ $20.32	$25.55M	1.2	1.54 million shs	72,566 shs
RNAZ TransCode Therapeutics	$1.73 +3.0%	$2.28	$1.52 ▼ $15.49	$29.29M	1.25	114,745 shs	43,132 shs

Options Trading Made Easy - Download Now

Learn the basics of options trading and how to use them to boost returns and manage risk with this free report from MarketBeat. Click the link below to get your free copy.

Get This Free Report

Compare Price Performance

Company	1-Day Performance	7-Day Performance	30-Day Performance	90-Day Performance	1-Year Performance
APRE Aprea Therapeutics	+1.16%	-5.59%	-22.48%	-14.02%	-59.18%
CNTX Context Therapeutics	-9.84%	-14.54%	-21.52%	-56.37%	-80.50%
EDSA Edesa Biotech	-3.06%	-23.39%	-32.62%	-58.52%	+12.20%
RNAZ TransCode Therapeutics	+3.07%	-5.62%	-0.59%	-80.67%	-87.57%

Compare Price & Volume

Company	Current Price	50-Day Moving Average	52-Week Range	Market Cap	Beta	Avg. Volume	Today's Volume
APRE Aprea Therapeutics	$0.58 -2.8%	$0.73	$0.55 ▼ $1.69	$7.34M	1.66	879,083 shs	74,287 shs
CNTX Context Therapeutics	$0.26 -7.1%	$0.40	$0.25 ▼ $3.62	$23.49M	1.71	1.75 million shs	954,340 shs
EDSA Edesa Biotech	$2.65 -7.0%	$4.46	$0.72 ▼ $20.32	$25.55M	1.2	1.54 million shs	72,566 shs
RNAZ TransCode Therapeutics	$1.73 +3.0%	$2.28	$1.52 ▼ $15.49	$29.29M	1.25	114,745 shs	43,132 shs

Options Trading Made Easy - Download Now

Learn the basics of options trading and how to use them to boost returns and manage risk with this free report from MarketBeat. Click the link below to get your free copy.

Get This Free Report

Compare Price Performance

Company	1-Day Performance	7-Day Performance	30-Day Performance	90-Day Performance	1-Year Performance
APRE Aprea Therapeutics	+1.16%	-5.59%	-22.48%	-14.02%	-59.18%
CNTX Context Therapeutics	-9.84%	-14.54%	-21.52%	-56.37%	-80.50%
EDSA Edesa Biotech	-3.06%	-23.39%	-32.62%	-58.52%	+12.20%
RNAZ TransCode Therapeutics	+3.07%	-5.62%	-0.59%	-80.67%	-87.57%

Compare Analyst Forecasts

Company	Consensus Rating Score	Consensus Rating	Consensus Price Target	% Upside from Current Price
APRE Aprea Therapeutics	2.50	Moderate Buy	$2.80	380.27% Upside
CNTX Context Therapeutics	2.50	Moderate Buy	$6.17	2,312.62% Upside
EDSA Edesa Biotech	2.67	Moderate Buy	$5.00	88.68% Upside
RNAZ TransCode Therapeutics	1.00	Sell	N/A	N/A

Current Analyst Ratings Breakdown

Latest APRE, EDSA, CNTX, and RNAZ Analyst Ratings

Date	Company	Brokerage	Action	Rating	Price Target
10/14/2026	APRE Aprea Therapeutics	LADENBURG THALM/SH SH Subscribe to MarketBeat All Access to unlock brokerage rankings	Initiated Coverage	Buy	$2.00
10/12/2026	CNTX Context Therapeutics	Zacks Research Subscribe to MarketBeat All Access to unlock brokerage rankings	Downgrade	Hold ➝ Strong Sell
9/21/2026	EDSA Edesa Biotech	Weiss Ratings Subscribe to MarketBeat All Access to unlock brokerage rankings	Reiterated Rating	Sell (E+)
9/3/2026	CNTX Context Therapeutics	Weiss Ratings Subscribe to MarketBeat All Access to unlock brokerage rankings	Downgrade	Sell (D-) ➝ Sell (E+)
8/20/2026	CNTX Context Therapeutics	Weiss Ratings Subscribe to MarketBeat All Access to unlock brokerage rankings	Upgrade	Sell (E+) ➝ Sell (D-)
8/13/2026	APRE Aprea Therapeutics	Wedbush Subscribe to MarketBeat All Access to unlock brokerage rankings	Lower Price Target	Outperform	$3.00
8/6/2026	CNTX Context Therapeutics	Citigroup Subscribe to MarketBeat All Access to unlock brokerage rankings	Reiterated Rating	Outperform
8/6/2026	CNTX Context Therapeutics	Weiss Ratings Subscribe to MarketBeat All Access to unlock brokerage rankings	Downgrade	Sell (D-) ➝ Sell (E+)
8/6/2026	CNTX Context Therapeutics	Lifesci Capital Subscribe to MarketBeat All Access to unlock brokerage rankings	Downgrade	Strong-Buy ➝ Hold
7/17/2026	APRE Aprea Therapeutics	Weiss Ratings Subscribe to MarketBeat All Access to unlock brokerage rankings	Reiterated Rating	Sell (E+)
7/17/2026	CNTX Context Therapeutics	Weiss Ratings Subscribe to MarketBeat All Access to unlock brokerage rankings	Reiterated Rating	Sell (D-)

(Data available from 10/14/2023 forward. View 10+ years of historical ratings with our analyst ratings screener.)

Compare Sales & Book Value

Company	Annual Revenue	Price/Sales	Cashflow	Price/Cash	Book Value	Price/Book
APRE Aprea Therapeutics	$290K	25.31	N/A	N/A	$1.52 per share	0.38
CNTX Context Therapeutics	N/A	N/A	N/A	N/A	$0.66 per share	N/A
EDSA Edesa Biotech	N/A	N/A	N/A	N/A	$0.45 per share	N/A
RNAZ TransCode Therapeutics	N/A	N/A	N/A	N/A	$11.27 per share	N/A

Compare Profitability & Earnings

Company	Net Income	EPS	Trailing P/E Ratio	Forward P/E Ratio	P/E Growth	Net Margins	Return on Equity (ROE)	Return on Assets (ROA)	Next Earnings Date
APRE Aprea Therapeutics	-$12.60M	-$1.08	N/A	N/A	N/A	N/A	-47.60%	-40.97%	11/11/2026 (Estimated)
CNTX Context Therapeutics	-$36.12M	-$0.48	N/A	N/A	N/A	N/A	-82.06%	-72.74%	11/4/2026 (Estimated)
EDSA Edesa Biotech	-$7.19M	-$1.69	N/A	N/A	N/A	N/A	-560.22%	-105.74%	12/11/2026 (Estimated)
RNAZ TransCode Therapeutics	-$34.66M	-$52.37	N/A	N/A	N/A	N/A	-875.35%	-37.46%	11/18/2026 (Estimated)

Latest APRE, EDSA, CNTX, and RNAZ Earnings

Date	Quarter	Company	Consensus Estimate	Reported EPS	Beat/Miss	Gap EPS	Revenue Estimate	Actual Revenue
11/11/2026	Q3 2026	APRE Aprea Therapeutics	-$0.08	N/A	N/A	N/A	$0.31 million	N/A
11/4/2026	Q3 2026	CNTX Context Therapeutics	-$0.09	N/A	N/A	N/A	N/A	N/A
8/14/2026	Q2 2026	RNAZ TransCode Therapeutics	N/A	-$7.17	N/A	-$7.17	N/A	N/A
8/13/2026	Q3 2026	EDSA Edesa Biotech	-$0.4350	-$0.60	-$0.1650	-$0.60	N/A	N/A
8/12/2026	Q2 2026	APRE Aprea Therapeutics	-$0.1775	-$0.07	+$0.1075	-$0.07	$0.25 million	N/A
8/5/2026	Q2 2026	CNTX Context Therapeutics	-$0.0921	-$0.15	-$0.0579	-$0.15	N/A	N/A

Compare Dividends

Company	Annual Payout	Dividend Yield	5-Year Annualized Dividend Growth	Payout Ratio	Years of Consecutive Growth
APRE Aprea Therapeutics	N/A	N/A	N/A	N/A	N/A
CNTX Context Therapeutics	N/A	N/A	N/A	N/A	N/A
EDSA Edesa Biotech	N/A	N/A	N/A	N/A	N/A
RNAZ TransCode Therapeutics	N/A	N/A	N/A	N/A	N/A

Compare Debt

Company	Debt-to-Equity Ratio	Current Ratio	Quick Ratio
APRE Aprea Therapeutics	N/A	13.56	13.56
CNTX Context Therapeutics	N/A	5.81	5.81
EDSA Edesa Biotech	N/A	2.76	2.76
RNAZ TransCode Therapeutics	N/A	1.97	1.97

Compare Ownership

Institutional Ownership

Company	Institutional Ownership
APRE Aprea Therapeutics	34.19%
CNTX Context Therapeutics	14.03%
EDSA Edesa Biotech	5.50%
RNAZ TransCode Therapeutics	N/A

Insider Ownership

Company	Insider Ownership
APRE Aprea Therapeutics	10.49%
CNTX Context Therapeutics	4.80%
EDSA Edesa Biotech	24.40%
RNAZ TransCode Therapeutics	0.10%

Compare Miscellaneous Stats

Company	Employees	Shares Outstanding	Free Float	Optionable
APRE Aprea Therapeutics	8	12.59 million	11.27 million	No Data
CNTX Context Therapeutics	15	91.88 million	87.47 million	Not Optionable
EDSA Edesa Biotech	17	9.64 million	7.29 million	Not Optionable
RNAZ TransCode Therapeutics	12	16.93 million	16.91 million	Not Optionable

APRE, EDSA, CNTX, and RNAZ Headlines

Recent News About These Companies

TransCode Therapeutics (NASDAQ:RNAZ) Stock Jumps 12.1% - Still a Buy?

October 6, 2026 | americanbankingnews.com

TransCode Therapeutics Prepays $840,975 on Convertible Notes to Yorkville, Secures Waiver on Amortization Events

October 3, 2026 | kalkinemedia.comK

TransCode Reports Continued Disease Stabilization and Extended Treatment Duration with TTX-MC138 in Ongoing Phase 1a Clinical Trial Follow-Up

September 28, 2026 | prnewswire.com

TransCode Therapeutics Announces Patent Advancements in Australia and Japan Strengthening Global IP Position in RNA-Based Immuno-Oncology

September 22, 2026 | prnewswire.com

TransCode Therapeutics, Inc. (RNAZ) Discusses Advancing Multi-Platform Oncology Pipeline Targeting Metastatic Cancer Transcript

September 16, 2026 | seekingalpha.com

Join Today’s Live Investor Webinar with TransCode Therapeutics

September 16, 2026 | usatoday.com

TransCode Therapeutics Announces Leadership Transition

September 10, 2026 | prnewswire.com

Join TransCode Therapeutics’ Live Investor Webinar: Advancing a Multi-Platform Oncology Pipeline Targeting Metastatic Cancer

September 3, 2026 | usatoday.com

TransCode Therapeutics Announces Publication Demonstrating Survival Benefit of TTX-MC138 in Preclinical Model of Breast Cancer Bone Metastasis

August 31, 2026 | prnewswire.com

Virax Biolabs and Transcode Therapeutics Interviews to Air Nationally on the RedChip Small Stocks, Big Money(TM) Show on CNBC and Bloomberg TV

August 7, 2026 | finance.yahoo.com

TransCode Therapeutics, Inc.

July 22, 2026 | edition.cnn.com

TransCode Therapeutics Inc RNAZ

July 3, 2026 | morningstar.comM

TransCode Therapeutics, Inc. (RNAZ) Discusses Strategic, Scientific, and Clinical Updates With Focus on TTX-MC138 Phase 2a Trial in Colorectal Cancer Prepared Remarks Transcript

June 18, 2026 | seekingalpha.com

RNAZ: Introducing RNA therapeutics

June 8, 2026 | msn.com

TransCode Therapeutics to Host R&D Webcast on June 18, 2026

June 8, 2026 | prnewswire.com

RNAZ Share News Today

June 4, 2026 | uk.investing.com

EXCLUSIVE: TransCode's RNA Therapeutic Achieves 64% Stable Disease Rate In Colorectal Cancer Phase 1 Study

June 3, 2026 | finance.yahoo.com

TransCode Therapeutics Successfully Completes Phase 1a Clinical Trial, Reports Safety and Stabilization Data for TTX-MC138 in Metastatic Cancer

June 3, 2026 | prnewswire.com

TransCode Therapeutics, Inc.: TransCode Therapeutics Initiates Phase 2a Clinical Trial with TTX-MC138 in Patients with ctDNA Positive Colorectal Cancer

May 28, 2026 | finanznachrichten.de

TransCode Therapeutics Initiates Phase 2a Clinical Trial with TTX-MC138 in Patients with ctDNA Positive Colorectal Cancer

May 27, 2026 | prnewswire.com

New MarketBeat Followers Over Time

Media Sentiment Over Time

APRE, EDSA, CNTX, and RNAZ Company Descriptions

Aprea Therapeutics NASDAQ:APRE

$0.58 -0.02 (-2.83%)

Closing price 04:00 PM Eastern

Extended Trading

$0.59 +0.01 (+1.37%)

As of 04:38 PM Eastern

Aprea Therapeutics, Inc., a clinical-stage biopharmaceutical company, focuses on developing and commercializing novel synthetic lethality-based cancer therapeutics that targets DNA damage response pathways. Its lead product candidate is the ATRN-119 that is in Phase I clinical trials for treating advanced solid tumors. The company is also developing ATRN-1051 for the treatment of ovarian cancer; and APRE-DDRi for the treatment of advanced solid tumors. The company is headquartered in Doylestown, Pennsylvania.

Context Therapeutics NASDAQ:CNTX

$0.26 -0.02 (-7.05%)

Closing price 04:00 PM Eastern

Extended Trading

$0.27 +0.02 (+6.03%)

As of 04:50 PM Eastern

Context Therapeutics Inc., a biopharmaceutical company, develops products for the treatment of solid tumors. Its lead program candidate is CTIM-76, an anti-Claudin 6 (CLDN6) x anti-CD3 bispecific antibody that is intended to redirect T-cell-mediated lysis toward malignant cells expressing CLDN6. The company has a collaboration and licensing agreement with Integral Molecular, Inc. for the development of a CLDN6 bispecific monoclonal antibody for cancer therapy. Context Therapeutics Inc. was incorporated in 2015 and is headquartered in Philadelphia, Pennsylvania.

Edesa Biotech NASDAQ:EDSA

$2.65 -0.20 (-7.02%)

Closing price 04:00 PM Eastern

Extended Trading

$2.71 +0.06 (+2.23%)

As of 05:18 PM Eastern

Edesa Biotech, Inc., a clinical-stage biopharmaceutical company, engages in the research and development, manufacture, and commercialization of pharmaceutical products for inflammatory and immune-related diseases. Its lead product candidates are EB05, a monoclonal antibody, which is in Phase 3 clinical study for the treatment of acute respiratory distress syndrome in Covid-19 patients; and EB01, a topical vanishing cream containing non-steroidal anti-inflammatory compound that has completed Phase 2b clinical study to treat chronic allergic contact dermatitis. The company also develops EB02, an extension of secretory phospholipase 2 anti-inflammatory cream for treating erythema, swelling, and exudation associated with hemorrhoids disease; and EB06, an anti- chemokine ligand 10 (CXCL10) monoclonal antibody in vitiligo. It has a collaboration agreement with NovImmune SA to develop monoclonal antibodies targeting products containing toll-like receptor 4 and CXCL10 for therapeutic, prophylactic, and diagnostic applications in humans and animals; and Yissum Research Development Company for the development of products for therapeutic, prophylactic, and diagnostic uses in topical dermal and anorectal applications, as well as for the use in dermatologic and gastrointestinal conditions. The company was founded in 2015 and is headquartered in Markham, Canada.

TransCode Therapeutics NASDAQ:RNAZ

$1.73 +0.05 (+2.98%)

Closing price 04:00 PM Eastern

Extended Trading

$1.75 +0.02 (+1.33%)

As of 05:36 PM Eastern

TransCode Therapeutics, Inc., a ribonucleic acid (RNA) oncology company, focuses on the development and commercialization of drugs and diagnostics for treating and identifying various cancers. Its lead therapeutic candidate is TTX-MC138 that targets microRNA-10b, a master regulator of metastatic cell viability in a range of cancers, including breast, pancreatic, ovarian, colon cancer, glioblastomas, and others. The company is also developing TTX-siPDL1, an siRNA-based modulator of programmed death-ligand 1; and TTX-siLIN28B, an siRNA-based inhibitor of RNA-binding protein LIN28B. In addition, the company developing TTX-RIGA, an RNA- based agonist of the retinoic acid-inducible gene I targeting activation of innate immunity in the tumor microenvironment; TTX-CRISPR, a CRISPR/Cas9-based therapy platform for the repair or elimination of cancer-causing genes inside tumor cells; and TTX-mRNA, an mRNA-based platform for the development of cancer vaccines that activate cytotoxic immune responses against tumor cells. TransCode Therapeutics, Inc. was incorporated in 2016 and is based in Boston, Massachusetts.

More Stock Comparisions from MarketBeat

More Stock Ideas from MarketBeat

Stock Lists

Low Priced Stocks

Stocks By Exchange

Latest Stock Ideas

Unlock superior investment research and tools.

Get MarketBeat All Access

In-depth profiles and analysis for 20,000 public companies.
Real-time analyst ratings, insider transactions, earnings data, and more.
Our daily ratings and market update email newsletter.

Sign In
Create Account

Your Email Address:

Your Password:

Forgot your password?

Your Email Address:

Choose a Password:

By creating a free account, you agree to our terms of service. This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.

Compare Stocks

Comparative Price Performance Over Time

Compare Price & Volume

Compare Price Performance

Compare Price & Volume

Compare Price Performance

Compare Analyst Forecasts

Current Analyst Ratings Breakdown

Latest APRE, EDSA, CNTX, and RNAZ Analyst Ratings

Compare Sales & Book Value

Compare Profitability & Earnings

Latest APRE, EDSA, CNTX, and RNAZ Earnings

Compare Dividends

Compare Debt

Compare Ownership

Institutional Ownership

Insider Ownership

Compare Miscellaneous Stats

APRE, EDSA, CNTX, and RNAZ Headlines

Recent News About These Companies

New MarketBeat Followers Over Time

Media Sentiment Over Time

APRE, EDSA, CNTX, and RNAZ Company Descriptions

Aprea Therapeutics NASDAQ:APRE

Context Therapeutics NASDAQ:CNTX

Edesa Biotech NASDAQ:EDSA

TransCode Therapeutics NASDAQ:RNAZ

More Stock Comparisions from MarketBeat

Stock Comparison Ideas (A-K)

Stock Comparison Ideas (L-Z)

More Stock Ideas from MarketBeat

Best-in-Class Portfolio Monitoring

Stock Ideas and Recommendations

Advanced Stock Screeners and Research Tools

About MarketBeat

MarketBeat Products

Popular Tools

Financial Calendars

Terms & Info

Compare Stocks

Comparative Price Performance Over Time

Compare Price & Volume

Compare Price Performance

Compare Price & Volume

Compare Price Performance

Compare Analyst Forecasts

Current Analyst Ratings Breakdown

Latest APRE, EDSA, CNTX, and RNAZ Analyst Ratings

Compare Sales & Book Value

Compare Profitability & Earnings

Latest APRE, EDSA, CNTX, and RNAZ Earnings

Compare Dividends

Compare Debt

Compare Ownership

Institutional Ownership

Insider Ownership

Compare Miscellaneous Stats

APRE, EDSA, CNTX, and RNAZ Headlines

Recent News About These Companies

New MarketBeat Followers Over Time

Media Sentiment Over Time

APRE, EDSA, CNTX, and RNAZ Company Descriptions

Aprea Therapeutics NASDAQ:APRE

Context Therapeutics NASDAQ:CNTX

Edesa Biotech NASDAQ:EDSA

TransCode Therapeutics NASDAQ:RNAZ

More Stock Comparisions from MarketBeat

Stock Comparison Ideas (A-K)

Stock Comparison Ideas (L-Z)

More Stock Ideas from MarketBeat

MarketBeat All Access Features

Best-in-Class Portfolio Monitoring

Stock Ideas and Recommendations

Advanced Stock Screeners and Research Tools